Posted Nov. 3, 2009 at 9:29 a.m.

Chelsea Therapeutics improves 3Q losses

Print this blog post

Get the latest news alerts: Follow LTW at Twitter

Local Tech Wire

CHARLOTTE, N.C. —  Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) reported a third-quarter loss of $7.1 million, improving on the year-ago loss of $10.1 million for the same quarter.

In figures it released Monday, Chelsea said the loss translated to 22 cents per share, down from the year-ago loss of 34 cents. The 2008 loss reflected a problem with some investments, the company said, and the loss without that charge would have been 27 cents.

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops products to treat a variety of diseases. Its most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine and is being developed for the treatment of neurogenic orthostatic hypotension.

Copyright 2010 Local Tech Wire. All rights reserved.
Editor’s Blog

Editor’s Blog

The latest blog posts from our Local Tech Wire and WRAL editors. Read more articles…

Featured